

- **Investment Rational**

XACT Robotics is advancing the field of radiology with cutting edge, hands-free robotic technologies, designed to address the over 20 million percutaneous procedures conducted globally each year. Our leadership team is comprised of start-up, robotic, and disruptive technology experts with deep knowledge and vast experience in the robotic market.

- **Business Strategy**

Short-term, our team is focused on organic growth of the business. We are expanding our commercial presence and creating centers of robotic excellence across Israel, U.S., and Europe. In addition, we are expediting our product development and clinicals to apply our technology across broader applications. Longer-term, we are looking at inorganic growth opportunities including partnerships and acquisitions that supplement our existing platform.

- **Core Technology**

The XACT ACE Robotic System is the world's first and only robotic system that integrates image guided planning and real time monitoring with non-linear steering. It is designed to enhance accuracy, consistency, and efficiency with precise robotic insertion of various instruments to a desired target during CT-guided percutaneous procedures. ACE is enabling hospitals to offer the most advanced solutions to patients, while enhancing the capabilities and safety of physicians and staff.

- **Product Profile/Pipeline**

We have a robust product development pipeline to enhance experience, expand usability, and establish standards. Our pipeline includes projects such as additional imaging modalities (i.e. cone beam CT, ultrasound, MRI), new device and tool insertion kits (i.e. ablation, drainage catheters), expanded clinical indications (i.e. lung, bone, brachytherapy), remote operation of the robot, and integration of AI.

- **What's Next?**

Our organization is growing at a rapid pace with a product that is revolutionizing the way care is provided to patients. We continue to educate and drive demand with providers on the benefits of robotic insertion while building the infrastructure, pipeline, and clinical validation that can sustain company growth for the long term.